Active Broker’s Concerns In Focus: FibroGen (NASDAQ:FGEN), DURECT Corporation (NASDAQ:DRRX)

FibroGen, Inc. (NASDAQ:FGEN) [Trend Analysis] knocking active thrust in leading trading session, shares a decrease of -1.17% to 21.54 with around 118266 shares have changed hands in this session. FibroGen, Inc. (FGEN) along with its unit FibroGen China declared positive topline results from the two Phase 3 clinical studies of roxadustat (FG-4592) designed to support new drug application submission in China.

Roxadustat is a first-in-class, orally administered small molecule for treatment of anemia in dialysis-dependent CKD (DD-CKD) and non-dialysis-dependent CKD (NDD-CKD) patients. The company noted that both of the Phase 3 studies met their primary efficacy endpoints, which were evaluated in the comparator-controlled portions of the studies. The stock is going forward its fifty-two week low with 49.82% and lagging behind from its 52-week high price with -16.17%.

Similar, the positive performance for the quarter recorded as 32.93% and for the year was 7.50%, while the YTD performance remained at 1.87%. FGEN has Average True Range for 14 days of 1.26.

Shares of DURECT Corporation (NASDAQ:DRRX) [Trend Analysis] swings enthusiastically in regular trading session, it a decrease of -2.25% to close at $1.05. DURECT Corporation (DRRX) provided that an update on the DUR-928 development program. DUR-928, our Epigenetic Regulator Program’s lead product candidate, is an endogenous, small molecule, new chemical entity (NCE), which may have broad applicability in several metabolic diseases such as nonalcoholic steatohepatitis (NASH) and other liver conditions, and in acute organ injuries such as acute kidney injury (AKI).

Phase 1b trial in patients with NASH; Our first patient trial utilizing DUR-928 was an open-label, single-ascending-dose safety and pharmacokinetic (PK) Phase 1b trial in liver function impaired (NASH) patients and matched control subjects (matched by age, body mass index and gender with normal liver function). This study was conducted in Australia in successive cohorts evaluating single-dose levels (first a low dose and then a high dose) of orally administered DUR-928. Moving forward to saw long-term intention, the experts calculate Return on Investment of -59.70%. The stock is going forward its fifty-two week low with 5.65% and lagging behind from its 52-week high price with -47.71%. DRRX last month stock price volatility remained 4.86%.

 

About Aaron Smithies

Aaron Smithies has a wide look on current monetary and financial events. He is an editor and a writer. His views; At Streetwise Report, we think the best opportunities arise from a complete understanding of all investing disciplines in order to identify the most attractive stocks at any given time. Interests: Biotech, Finical markets, Dividend stock ideas & income, Energy stocks, Consumer goods stocks

Leave a Reply

Your email address will not be published. Required fields are marked *